Encephalitis, Japanese clinical trials
The registry lists 74 studies for Encephalitis, Japanese across more than 10 countries. 3 are recruiting or about to start. 65 of them are mainly about Encephalitis, Japanese (how this is decided). Per ClinicalTrials.gov, last updated 2026-09-11.
Get an email when these change. Save the Encephalitis, Japanese studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Valneva Austria GmbH (15) · Sanofi Pasteur, a Sanofi Company (11) · PATH (7) · Sanofi (7) · Liaoning Chengda Biotechnology CO., LTD (4) · National Institute of Hygiene and Epidemiology, Vietnam (3) · Novartis (2) · University of Liverpool (2)
What is being tested here
Drugs under test in Encephalitis, Japanese studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Jan 2027Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus · ANRS, Emerging Infectious Diseases
Who these studies take
Of the 2 Encephalitis, Japanese studies recruiting now, 0 (0%) set no upper age limit and 2 (100%) stop at 75 or younger. 1 (50%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (50%) | 1 (50%) |
| 18 | 1 (50%) | 1 (50%) |
| 30 | 2 (100%) | 2 (100%) |
| 40 | 2 (100%) | 2 (100%) |
| 50 | 1 (50%) | 1 (50%) |
| 65 | 1 (50%) | 1 (50%) |
| 75 | 1 (50%) | 1 (50%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 74 studies, recruiting or not: 69% stop at 75 or younger and 65% at 65; 62% take children; 0% are for women only and 0% for men only; 93% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 74. Browse all 74 → or search them.
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis VirusNot yet recruitingNCT06674837
- An Experimental Medicine Decipher of a Minimum Correlate of Cellular ImmunityRecruitingNCT05568953Phase 21 country
- A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy AdultsCompletedNCT06680128Phase 1/22 countries
- Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese EncephalitisActive, not recruitingNCT06825312Phase 41 country
- Safety Observation of the Japanese Encephalitis Vaccine Given With a Primary ImmunizationCompletedNCT063726651 country
- Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)CompletedNCT06331702Phase 41 country
- Flavivirus Cross-priming Potential of IMOJEVCompletedNCT03920111Not applicable1 country
- Monitoring JE Antibody Levels in Healthy Populations and Immunization Strategy in Low-Prevalence AreasActive, not recruitingNCT06678373Phase 41 country
- Immunogenicity Study of the Japanese Encephalitis Vaccine IC51CompletedNCT00604708Phase 3
- Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00594958Phase 3
- Safety and Tolerability of the Japanese Encephalitis Vaccine IC51CompletedNCT00605085Phase 3
- Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang ProvinceStatus unknownNCT04817917Phase 41 country
- Postmarketing Surveillance Study for IMOJEV® in Republic of KoreaCompletedNCT029337101 country
- Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South KoreaCompletedNCT01900444Phase 31 country
- Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy SubjectsCompletedNCT02492165Phase 31 country
- Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CVCompletedNCT01190228Phase 31 country
- Purified Inactivated Japanese Encephalitis VaccineStatus unknownNCT04223037Phase 31 country
- Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster DoseCompletedNCT02514746Phase 4
- Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) VaccineCompletedNCT02880865Phase 41 country
- Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE VaccineCompletedNCT00463476Phase 41 country
- Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-StudyCompletedNCT01246479Phase 33 countries
- Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles VaccineCompletedNCT00249769Phase 31 country
- SouthEast Asia Encephalitis ProjectStatus unknownNCT040894364 countries
- Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals.Status unknownNCT03971058Phase 41 country
- A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2CompletedNCT01656200Phase 41 country
- Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of AgeCompletedNCT00463684Phase 41 country
- Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 VaccineCompletedNCT01567865Phase 41 country
- Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in VietnamCompletedNCT03282370Phase 31 country
- Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of AgeCompletedNCT03204227Phase 21 country
- Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in ToddlersCompletedNCT01001988Phase 32 countries
- Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis VaccineinjCompletedNCT02532569Phase 41 country
- A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese InfantsCompletedNCT02367664Phase 31 country
- Immunogenicity of Co-administration of Measles and Japanese Encephalitis VaccinesCompletedNCT02643433Phase 41 country
- Safety and Immunogenicity of JECEVAX in Young ChildrenCompletedNCT02816554Phase 21 country
- Post-licensure Safety Study of IMOJEV® in ThailandCompletedNCT01981967Phase 41 country
- Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post FillingCompletedNCT00776230Phase 32 countries
- The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in HumansCompletedNCT01943305Phase 21 country
- Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 VaccineCompletedNCT02602652Not applicable
- Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the PhilippinesCompletedNCT00735644Phase 32 countries
- Safety Surveillance After Immunization With IXIAROCompletedNCT013354121 country
- Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic CountryCompletedNCT01296360Phase 31 country
- Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult SubjectsCompletedNCT01662440Phase 33 countries
- Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai ChildrenCompletedNCT01408537Phase 31 country
- Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles VaccineCompletedNCT00412516Phase 31 country
- Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and ChildrenCompletedNCT00621764Phase 21 country
- Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese ToddlersCompletedNCT01188343Phase 31 country
- Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51CompletedNCT00596102
- Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51CompletedNCT00595309Phase 32 countries
- Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51CompletedNCT00595465Phase 32 countries